Drugs / Ibuprofen
Regulatory milestones approvals, filings & regulatory actions · 14 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | CALDOLOR | — | 2015-11-20 – 2026-01-23 | fda.gov ↗ |
| Label expansion | US (FDA) | MIDOL LIQUID GELS | — | 2006-03-13 | fda.gov ↗ |
| Approved | EU (EMA) | Pedea | — | 2004-07-28 | europa.eu ↗ |
| Label expansion | US (FDA) | ADVIL LIQUI-GELS | — | 2000-03-16 | fda.gov ↗ |
| Label expansion | US (FDA) | MOTRIN MIGRAINE PAIN | — | 2000-02-25 | fda.gov ↗ |
| Label expansion | US (FDA) | INFANT'S ADVIL | — | 2000-01-12 | fda.gov ↗ |
| Label expansion | US (FDA) | CHILDREN'S MOTRIN | — | 1999-04-15 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | MOTRIN | — | 1976-05-03 – 1995-03-24 | fda.gov ↗ |
| Approved | US (FDA) | MOTRIN | — | 1974-09-19 | fda.gov ↗ |
Trials 365 · started per year
today
US approved 1974
EU approved 2004
1
1
1
1
10
5
8
11
8
13
4
11
12
13
23
17
17
19
15
24
12
21
18
12
20
19
23
12
13
19741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 010 trials | ||||||
| Phase 0 | NCT07603934 | Dec 2025 → Aug 2026 overdue | dental pulp necrosis | Cairo University | Recruiting | No outcome recorded |
| Phase 0 | NCT07114198 | Aug 2025 | pulpitis | Inonu University | Completed | No outcome recorded |
| Phase 0 | NCT06514222 | Jul → Aug 2024 overdue | impacted teeth, multiple | University of Sharjah | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06808529 | Jan → May 2024 | primary dysmenorrhea | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT05819619 | Jul 2023 → Apr 2024 | — | Hackensack Meridian Health | Terminated | No outcome recorded |
| Phase 0 | NCT05695664 | Aug 2021 → Jan 2022 | — | Benazir Bhutto Hospital, Rawalpindi | Completed | No outcome recorded |
| Phase 0 | NCT04612920 | Dec 2020 → Mar 2023 | — | University of Oklahoma | Completed | No outcome recorded |
| Phase 0 | NCT03953729 | Apr 2019 → Oct 2021 | anxiety | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 0 | NCT03243032 | Oct → Nov 2017 | neuropathy, painful | Satheesh Elangovan | Withdrawn | No outcome recorded |
| Phase 0 | NCT02463383 | Sep 2013 → Oct 2014 | breast cancer | Professor Lars Ove Dragsted | Completed | No outcome recorded |
| Phase 143 trials | ||||||
| Phase 1 | NCT07632274 | Jun → Sep 2026 expected | — | HALEON | Recruiting | No outcome recorded |
| Phase 1 | NCT07036861 | Nov 2023 → Apr 2024 | — | Berlin-Chemie Menarini | Completed | No outcome recorded |
| Phase 1 | NCT06077786 | Oct 2023 → May 2024 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT05927922 | Jun 2023 → Jun 2024 | pulpitis | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT06247462 | Jun → Sep 2023 | acute kidney injury | University of New Mexico | Completed | No outcome recorded |
| Phase 1 | NCT05341999 | Apr 2022 → Apr 2023 | pulpitis | Cairo University | Unknown | No outcome recorded |
| Phase 1 | NCT05512013 | Feb 2022 → Apr 2023 | bone resorption disease, disease of bone structure | United States Army Research Institute of Environmental Medicine | Completed | No outcome recorded |
| Phase 1 | NCT05329454 | Dec 2020 → Feb 2021 | chronic pain syndrome | Overseas Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04570644 | Aug 2020 → Jan 2021 | Alzheimer disease | AZTherapies, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03893175 | May 2019 → Mar 2022 | impacted teeth, multiple | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT05428306 | Oct → Nov 2018 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT03639571 | Aug → Oct 2018 | — | Medherant Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03418805 | Dec 2017 → Dec 2020 | — | Overseas Pharmaceuticals, Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT03225352 | Aug → Oct 2017 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03103022 | Jun 2017 → Apr 2019 | patent ductus arteriosus | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT03180879 | Apr → Jun 2017 | — | Reckitt Benckiser Healthcare (UK) Limited | Completed | No outcome recorded |
| Phase 1 | NCT03018015 | Sep → Oct 2016 | — | SocraTec R&D GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03184766 | Aug 2016 → Jan 2017 | — | Reckitt Benckiser Healthcare (UK) Limited | Completed | No outcome recorded |
| Phase 1 | NCT02521207 | Jul → Aug 2015 | gastroduodenitis | Oxford Pharmascience Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02482324 | Jun → Jul 2015 | — | AZTherapies, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03497715 | Apr → Jul 2015 | — | Reckitt Benckiser Healthcare (UK) Limited | Terminated | No outcome recorded |
| Phase 1 | NCT02666846 | Mar → May 2015 | — | Futura Medical Developments Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02482155 | Feb → Mar 2015 | — | Angelini Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02233582 | Sep 2014 → Oct 2016 | altitude sickness | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT03429738 | Apr → May 2014 | headache disorder | Institute for Pharmacology and Preventive Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01986660 | Oct 2013 | — | Strategic Science & Technologies, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01859377 | May → Jun 2013 | — | Pierre Fabre Laboratories | Completed | No outcome recorded |
| Phase 1 | NCT01771822 | Jan → Feb 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01734759 | Nov 2012 → Jan 2013 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01188317 | Jun 2010 → Sep 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01055249 | Jan → Jun 2010 | — | X-pert Med GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01064726 | Oct 2009 → Apr 2010 | allergic rhinitis | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00867880 | Mar → May 2009 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00411190 | Oct → Dec 2006 | osteoarthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00864526 | Oct 2006 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00864357 | Oct 2006 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00442585 | Sep 2006 → Oct 2007 | — | Gebro Pharma GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00239746 | Oct 2005 → Aug 2009 | Alzheimer disease | National Institute on Aging (NIA) | Unknown | No outcome recorded |
| Phase 1 | NCT00372801 | Aug 2005 → ? | osteoarthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00833157 | Feb 2005 → Jul 2007 | osteoarthritis, knee | Bispebjerg Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT00921830 | Apr → Jul 2004 | — | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 1 | NCT00223691 | Mar 2002 → Jan 2017 | autonomic nervous system disorder, orthostatic hypotension | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT02182960 | Sep → Oct 1998 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT06088732 | Mar 2024 → Dec 2026 expected | bipolar depression | Laureate Institute for Brain Research, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05742763 | Nov 2023 → Oct 2024 | osteoarthritis, knee | QC Kinetix LLC | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04964622 | Dec 2021 → Jul 2022 | pulpitis | Cairo University | Completed | No outcome recorded |
| Phase 1/2 | NCT03528343 | Sep → Dec 2017 | appendicitis | University of Utah | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03184649 | May → Sep 2017 | — | Cairo University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02602483 | Dec 2015 → Dec 2016 | temporomandibular joint disorder | Spherium Biomed | Completed | No outcome recorded |
| Phase 1/2 | NCT00111046 | Feb 2001 → Feb 2004 | malignant choroid melanoma | Royal Liverpool University Hospital | Unknown | No outcome recorded |
| Phase 242 trials | ||||||
| Phase 2 | NCT06342830 | Jun 2024 → Sep 2025 | periapical periodontitis | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT06152796 | Dec 2023 → Sep 2025 | patent ductus arteriosus | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT05842044 | Sep 2023 → Sep 2026 expected | renal carcinoma | University of Miami | Recruiting | No outcome recorded |
| Phase 2 | NCT04772781 | Jun 2022 → May 2023 | — | Apsen Farmaceutica S.A. | Completed | No outcome recorded |
| Phase 2 | NCT04676802 | Dec 2021 → Feb 2027 expected | neuropathy, painful, osteoarthritis, hand | Stanford University | Recruiting | No outcome recorded |
| Phase 2 | NCT03792295 | Jul → Dec 2021 | — | Khashayar Vaziri | Withdrawn | No outcome recorded |
| Phase 2 | NCT04575519 | Mar 2021 → Dec 2023 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Germans Trias i Pujol Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT03949478 | Feb 2021 → Jan 2025 | epilepsy | University of Calgary | Unknown | No outcome recorded |
| Phase 2 | NCT04907864 | Jan 2020 → Mar 2022 | biliary tract cancer, colorectal cancer, gastric cancer, lung cancer +1 | Kil Yeon Lee | Unknown | No outcome recorded |
| Phase 2 | NCT04485403 | Sep 2019 → Dec 2021 | polycystic ovary syndrome | Poznan University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT03978767 | Jun 2019 → Jun 2026 | severe pre-eclampsia | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT03767933 | Apr 2019 → Mar 2023 | musculoskeletal system disorder | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT03399318 | Jan 2019 → Dec 2022 | epilepsy, malaria, parasitemia | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT03332524 | Jan 2018 → Sep 2019 | sunburn | Sephoris Pharmaceuticals LLC | Terminated | No outcome recorded |
| Phase 2 | NCT03186638 | May 2017 → Mar 2022 | cancer, cognitive impairment with or without cerebellar ataxia | University of Rochester NCORP Research Base | Completed | No outcome recorded |
| Phase 2 | NCT02781909 | Sep 2016 → Jan 2019 | tuberculosis | Germans Trias i Pujol Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02571543 | Jan 2016 → Aug 2022 | anovulation, pregnancy disorder | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 2 | NCT03055247 | Nov 2015 → Jul 2023 overdue | granulomatous disease, chronic, X-linked | IRCCS San Raffaele | Recruiting | No outcome recorded |
| Phase 2 | NCT02580344 | Oct 2015 → Sep 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02531451 | Sep 2015 → Jun 2016 | — | Karolinska Institutet | Completed | No outcome recorded |
| Phase 2 | NCT02443142 | May 2015 → Jul 2016 | traumatic brain injury | Northwestern University | Withdrawn | No outcome recorded |
| Phase 2 | NCT02344225 | Jan 2015 → Jun 2018 | retinopathy of prematurity | State University of New York - Downstate Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02339129 | Nov 2014 → Feb 2015 | — | Strategic Science & Technologies, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02241512 | Sep 2014 → Sep 2018 | acute pancreatitis | University of Texas Southwestern Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT02133326 | Mar 2014 → Jan 2017 | impacted teeth, multiple | Tufts University School of Dental Medicine | Unknown | No outcome recorded |
| Phase 2 | NCT02006576 | Jan 2014 → Mar 2018 | pulmonary emphysema | University of Nebraska | Completed | No outcome recorded |
| Phase 2 | NCT01958320 | Dec 2013 → Jun 2017 | intestinal perforation, necrotizing enterocolitis, patent ductus arteriosus | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT02417337 | Aug 2012 → Aug 2014 | pulpitis | University of Khartoum | Completed | No outcome recorded |
| Phase 2 | NCT01606527 | Jul → Oct 2012 | altitude sickness | Naval Health Research Center | Unknown | No outcome recorded |
| Phase 2 | NCT01605903 | May 2012 → Feb 2017 | adenoid hypertrophy, tonsillitis | Massachusetts Eye and Ear Infirmary | Completed | No outcome recorded |
| Phase 2 | NCT01559259 | Apr → Sep 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01291654 | Apr 2012 → Dec 2014 | patent ductus arteriosus | Shaare Zedek Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01535079 | Feb → Nov 2012 | acute pharyngitis | Pierre Fabre Laboratories | Completed | No outcome recorded |
| Phase 2 | NCT01496326 | Feb → Aug 2011 | osteoarthritis | BioChemics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01293968 | Nov 2010 → Jan 2011 | aphthous stomatitis | Qazvin University Of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01070745 | Jun 2010 → Jun 2012 | patent ductus arteriosus | Shaare Zedek Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT00913627 | May → Aug 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00758836 | Dec 2008 → Aug 2009 | migraine disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00644319 | Mar 2007 → Sep 2009 | metastatic malignant neoplasm | Oxford University Hospitals NHS Trust | Unknown | No outcome recorded |
| Phase 2 | NCT00121563 | Jul 2005 → Feb 2006 | — | National Institute of Nursing Research (NINR) | Completed | No outcome recorded |
| Phase 2 | NCT00528658 | Jan 2005 → Dec 2008 | — | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 2 | NCT00240812 | ? → Nov 2002 | enuresis | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT06046105 | Sep 2023 → Mar 2024 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04414995 | Jun → Nov 2020 | — | Indonesia University | Completed | No outcome recorded |
| Phase 2/3 | NCT03786029 | Apr → Jun 2019 | — | Latakia University | Completed | No outcome recorded |
| Phase 2/3 | NCT03789058 | Apr 2018 → Dec 2021 | impacted teeth, multiple | Jordan University of Science and Technology | Unknown | No outcome recorded |
| Phase 2/3 | NCT03055507 | Apr → Dec 2017 | chronic rhinosinusitis | University of Washington | Completed | No outcome recorded |
| Phase 2/3 | NCT02538237 | Nov 2013 → Aug 2014 | periodontitis | Islamic Azad University, Sanandaj | Completed | No outcome recorded |
| Phase 2/3 | NCT01988298 | Oct 2013 → Feb 2015 | hypertensive disorder | Complejo Hospitalario Dr. Arnulfo Arias Madrid | Completed | No outcome recorded |
| Phase 2/3 | NCT01243996 | Jun 2008 → May 2010 | patent ductus arteriosus | University of Florence | Completed | No outcome recorded |
| Phase 374 trials | ||||||
| Phase 3 | NCT07225140 | Oct 2026 → Oct 2027 expected | — | AFT Pharmaceuticals, Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07682558 | Oct 2026 → Nov 2029 expected | — | University Hospital, Basel, Switzerland | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07225634 | Sep 2026 → Mar 2027 expected | — | AFT Pharmaceuticals, Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06686862 | Apr 2025 → Apr 2027 expected | acute myocarditis | National Center for Cardiovascular Research Carlos III | Recruiting | No outcome recorded |
| Phase 3 | NCT06731556 | Dec 2024 | — | Bezmialem Vakif University | Completed | No outcome recorded |
| Phase 3 | NCT06531707 | May 2024 → Jan 2025 overdue | common cold | Laboratorios Silanes S.A. de C.V. | Recruiting | No outcome recorded |
| Phase 3 | NCT05081102 | Mar → May 2024 | — | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 3 | NCT06317064 | Mar → Oct 2024 | primary dysmenorrhea | Lahore Medical Research Center, LLP | Completed | No outcome recorded |
| Phase 3 | NCT05013567 | Aug 2022 → May 2023 | musculoskeletal system disorder | Brainfarma | Unknown | No outcome recorded |
| Phase 3 | NCT04813991 | Mar 2022 → Sep 2025 | — | Hackensack Meridian Health | Withdrawn | No outcome recorded |
| Phase 3 | NCT05011149 | Jan 2022 → Sep 2024 | patent ductus arteriosus | IWK Health Centre | Unknown | No outcome recorded |
| Phase 3 | NCT05000281 | Sep 2021 → Sep 2024 | — | Major Extremity Trauma Research Consortium | Unknown | No outcome recorded |
| Phase 3 | NCT02904304 | Dec 2020 → Jul 2021 | — | Ache Laboratorios Farmaceuticos S.A. | Suspended | No outcome recorded |
| Phase 3 | NCT04429282 | Jun 2020 | — | Yi Feng, MD | Unknown | No outcome recorded |
| Phase 3 | NCT04157036 | Feb 2020 → Sep 2021 | pulpitis | Walter Reed National Military Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT04005755 | Jul 2019 → Jun 2020 | — | AFT Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03785756 | Apr 2019 → Feb 2020 | — | Reckitt Benckiser Healthcare (UK) Limited | Completed | No outcome recorded |
| Phase 3 | NCT03907176 | Apr 2019 → Oct 2021 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT04476069 | Jan → Mar 2019 | — | Princess Nourah Bint Abdulrahman University | Completed | No outcome recorded |
| Phase 3 | NCT03722238 | Dec 2018 → Oct 2019 | — | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT03554018 | Oct 2018 → Sep 2019 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02929589 | Jul 2018 → Aug 2021 | — | Mike O'Callaghan Military Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT03330119 | Oct 2017 → Jun 2018 | pregnancy disorder, substance-related disorder | Brest, Norman A., M.D. | Terminated | No outcome recorded |
| Phase 3 | NCT02839785 | Mar 2017 → Sep 2018 | cerebral palsy | University Hospital, Brest | Terminated | No outcome recorded |
| Phase 3 | NCT04282941 | Feb 2017 → Jan 2020 | patent ductus arteriosus | Instituto de Investigación Hospital Universitario La Paz | Unknown | No outcome recorded |
| Phase 3 | NCT03003000 | Dec 2016 → Sep 2017 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01938144 | Apr → Nov 2016 | common cold | Pfizer | Withdrawn | No outcome recorded |
| Phase 3 | NCT02477007 | Dec 2015 → Nov 2018 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT02597634 | Nov 2015 → Oct 2016 | — | Strategic Science & Technologies, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02330926 | Apr 2015 → Apr 2023 | hypoproteinemia, hypercatabolic, neoplasm | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 3 | NCT02294019 | Nov 2014 → May 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02141139 | Sep 2014 → Jan 2016 | breast neoplasm | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT01945034 | Nov 2013 → Feb 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01929031 | Aug 2013 → Mar 2014 | neuropathy, painful, tooth disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01794923 | Jun 2013 → Mar 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01785862 | Feb → Jun 2013 | acute pharyngitis | Pierre Fabre Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT01606319 | Feb 2013 → Apr 2015 | asthma | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01426971 | Dec 2012 → Jun 2013 | — | Sanofi | Withdrawn | No outcome recorded |
| Phase 3 | NCT02441530 | Nov 2012 → Jan 2013 | primary dysmenorrhea | Bezmialem Vakif University | Completed | No outcome recorded |
| Phase 3 | NCT01789606 | Sep 2012 → Jun 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01680939 | May 2012 → Dec 2013 | obstructive sleep apnea syndrome | Hamilton Health Sciences Corporation | Unknown | No outcome recorded |
| Phase 3 | NCT02254525 | May 2012 → Jun 2014 | — | Biomendi S.A.U. | Terminated | No outcome recorded |
| Phase 3 | NCT01630278 | Mar 2012 → Jun 2019 | patent ductus arteriosus | Nantes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01563289 | Feb → Jul 2012 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01562717 | Feb → Oct 2012 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01462370 | Nov 2011 → Jun 2012 | primary dysmenorrhea | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT01332253 | Jul 2011 → Jul 2012 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01383486 | Jul → Aug 2011 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01362491 | Jun 2011 → Mar 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01266161 | Nov 2010 → Mar 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01172405 | Oct 2010 → Oct 2012 | headache disorder | Mantecorp Industria Quimica e Farmaceutica Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01216163 | Oct 2010 → Jan 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01002573 | Jul 2010 → Jun 2013 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01098747 | Apr → Jul 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01035346 | Jan 2010 → May 2011 | infectious disease | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00997074 | Oct 2009 → Oct 2010 | pregnancy disorder | Sheba Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00984815 | Sep 2009 → Jul 2011 | complex regional pain syndrome, osteoarthritis, rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01593163 | May 2009 → Mar 2010 | patent ductus arteriosus | Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz | Completed | No outcome recorded |
| Phase 3 | NCT01229449 | Jan → Sep 2009 | — | Reckitt Benckiser Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00707057 | Jun → Oct 2008 | — | SCOLR Pharma, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00631111 | Nov 2007 → Apr 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00606489 | Nov 2007 → May 2009 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00470600 | May 2007 → Sep 2008 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00450216 | Mar 2007 → Aug 2008 | ulcer disease | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00147355 | Nov 2005 → Nov 2008 | HIV infectious disease | Kirby Institute | Terminated | No outcome recorded |
| Phase 3 | NCT00225706 | Oct 2005 → Aug 2007 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00150280 | Oct 2004 → Jul 2005 | neuropathy, painful | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00092755 | Apr → Nov 2003 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00269191 | Feb → Nov 2003 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00440804 | Dec 2002 → Aug 2005 | patent ductus arteriosus | Farmacon | Completed | No outcome recorded |
| Phase 3 | NCT01131000 | Jun 2002 → Aug 2005 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00243815 | Jun 2002 → Nov 2004 | — | FHI 360 | Completed | No outcome recorded |
| Phase 3 | NCT00485160 | Feb 2002 → Sep 2006 | patent ductus arteriosus | Shaare Zedek Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00000574 | Sep 1990 → Jul 1995 | adult acute respiratory distress syndrome | Vanderbilt University | Completed | No outcome recorded |
| Phase 4106 trials | ||||||
| Phase 4 | NCT07687394 | Jul 2026 → Oct 2028 expected | gastric neoplasm | Yonsei University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07512297 | Apr → Dec 2026 expected | nephrolithiasis, ureterolithiasis | University of Gaziantep | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07571252 | Apr → Dec 2026 expected | — | University of Puerto Rico | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07459049 | Dec 2025 → Jun 2026 overdue | periodontitis | University of Baghdad | Recruiting | No outcome recorded |
| Phase 4 | NCT07565012 | Oct 2025 → Mar 2026 | periapical periodontitis, pulpitis | Armed Forces Institute of Dentistry, Pakistan | Completed | No outcome recorded |
| Phase 4 | NCT07424001 | Sep 2025 → Jan 2026 | — | Mehmet Çiğdem | Completed | No outcome recorded |
| Phase 4 | NCT07024199 | Sep 2025 → Jun 2027 expected | acute pancreatitis | Medical University of Warsaw | Recruiting | No outcome recorded |
| Phase 4 | NCT06860711 | Jul 2025 → Jun 2028 expected | chronic kidney disease | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 4 | NCT07076069 | Jul 2025 → Jun 2028 expected | rotator cuff syndrome | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT07070050 | May 2025 → May 2026 overdue | — | Federal Research and Clinical Centre of Intensive Care Medicine and Rehabilitology | Recruiting | No outcome recorded |
| Phase 4 | NCT06757075 | Apr 2025 → Mar 2027 expected | — | Boston University | Recruiting | No outcome recorded |
| Phase 4 | NCT06671002 | Jan 2025 → Oct 2026 expected | — | University of Michigan | Recruiting | No outcome recorded |
| Phase 4 | NCT06479122 | Oct 2024 → Jun 2026 overdue | — | Seoul National University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06604598 | Oct → Nov 2024 | nephrolithiasis | Universitas Jenderal Soedirman | Completed | No outcome recorded |
| Phase 4 | NCT06113211 | Oct 2024 → Sep 2026 expected | disease of bone structure, substance-related disorder | Henry Ford Health System | Recruiting | No outcome recorded |
| Phase 4 | NCT06398054 | Oct 2024 → Oct 2026 expected | — | ASST Fatebenefratelli Sacco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06505148 | Aug 2024 → Aug 2025 overdue | — | Baylor Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06495632 | Aug 2024 → Jul 2026 overdue | — | Cape Fear Valley Health System | Recruiting | No outcome recorded |
| Phase 4 | NCT06478758 | Feb → Apr 2024 | — | Giresun University | Completed | No outcome recorded |
| Phase 4 | NCT05761015 | Dec 2023 → Apr 2028 expected | chronic pain syndrome, osteoarthritis, hip, osteoarthritis, knee | University Hospital, Clermont-Ferrand | Recruiting | No outcome recorded |
| Phase 4 | NCT06061575 | Oct 2023 → Oct 2024 | infectious disease with sepsis, paracetamol poisoning | Ankara City Hospital Bilkent | Completed | No outcome recorded |
| Phase 4 | NCT05919745 | Oct 2023 → Dec 2026 expected | — | Marquette University | Recruiting | No outcome recorded |
| Phase 4 | NCT06060236 | Sep 2023 → Sep 2024 | disease of bone structure | Ankara City Hospital Bilkent | Unknown | No outcome recorded |
| Phase 4 | NCT05834569 | Jun 2023 → Jan 2025 | delirium, lung neoplasm | Korea University Guro Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT05575700 | Apr 2023 → Aug 2025 | arthropathy | Naestved Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05722002 | Feb 2023 → Dec 2026 expected | neuropathy, painful | University of Michigan | Recruiting | No outcome recorded |
| Phase 4 | NCT05602064 | Nov 2022 → Feb 2023 | — | Alexandria University | Completed | No outcome recorded |
| Phase 4 | NCT05763836 | Nov 2022 → Mar 2023 | supratentorial cancer | Ankara University | Unknown | No outcome recorded |
| Phase 4 | NCT05629494 | Sep 2022 → Mar 2026 overdue | prostate cancer, prostatitis | Albany Medical College | Recruiting | No outcome recorded |
| Phase 4 | NCT05512754 | Aug 2022 → Dec 2027 expected | — | University of Chicago | Recruiting | No outcome recorded |
| Phase 4 | NCT05076110 | Apr 2022 → Oct 2025 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT05190341 | Mar 2022 → Oct 2024 | female infertility | Madigan Army Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT06232785 | Feb 2022 → Oct 2023 | motion sickness | Second Hospital of Jilin University | Completed | No outcome recorded |
| Phase 4 | NCT06064175 | Jan → Dec 2022 | — | Ankara City Hospital Bilkent | Completed | No outcome recorded |
| Phase 4 | NCT04905563 | Jun 2021 → Jan 2024 | — | Le Bonheur Children's Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT05479747 | Jun → Dec 2021 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT04611529 | Mar 2021 → Jun 2023 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04533568 | Sep 2020 → Dec 2021 | migraine without aura | Kecioren Education and Training Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04334629 | May 2020 → May 2021 | COVID-19, respiratory system disorder | King's College London | Withdrawn | No outcome recorded |
| Phase 4 | NCT04123873 | Mar 2020 → Nov 2022 | arthropathy | Naestved Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02985177 | Jan 2020 → Jul 2021 | — | St. Justine's Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT05332314 | Nov 2019 → Jan 2024 | — | University of Louisville | Unknown | No outcome recorded |
| Phase 4 | NCT04947566 | Sep 2019 → Feb 2020 | neuropathy, painful | Fatima Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03375593 | Aug 2019 → Oct 2021 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| Phase 4 | NCT03861611 | Jul 2019 → Feb 2021 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT06187584 | Apr 2019 → Dec 2023 | — | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| Phase 4 | NCT03783702 | Apr 2019 → Jul 2020 | drug dependence, opioid abuse, sinusitis | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT03759028 | Feb 2019 → Dec 2027 expected | — | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 4 | NCT03749616 | Jan 2019 → Mar 2022 | — | University of Missouri-Columbia | Terminated | No outcome recorded |
| Phase 4 | NCT03918135 | Jan 2019 → Jan 2020 | — | Pamukkale University | Completed | No outcome recorded |
| Phase 4 | NCT04609254 | Dec 2018 → Apr 2020 | — | Pamukkale University | Completed | No outcome recorded |
| Phase 4 | NCT04372264 | Oct 2018 → May 2020 | migraine disorder | Pamukkale University | Unknown | No outcome recorded |
| Phase 4 | NCT04102566 | Dec 2017 → Oct 2019 overdue | benign prostatic hyperplasia | Benaroya Research Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT02583399 | Aug 2017 → Jul 2019 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02932579 | Jul 2017 → Jan 2021 | — | University of Rochester | Terminated | No outcome recorded |
| Phase 4 | NCT03523988 | May → Jun 2017 | — | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT02902172 | Mar → Oct 2017 | hypertensive disorder | St. Louis University | Terminated | No outcome recorded |
| Phase 4 | NCT03622489 | Mar 2017 → Aug 2018 | — | Wolfson Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02836509 | Sep → Dec 2016 | — | Pamukkale University | Unknown | No outcome recorded |
| Phase 4 | NCT03169127 | Apr 2016 → Jul 2018 | impacted teeth, multiple | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT01974609 | Mar 2016 → Feb 2022 | carpal tunnel syndrome | Horizon Health Network | Completed | No outcome recorded |
| Phase 4 | NCT02777320 | Mar → Aug 2016 | sciatica | Pamukkale University | Unknown | No outcome recorded |
| Phase 4 | NCT02686021 | Feb 2016 → Apr 2021 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT02778958 | Jan 2016 → Jan 2017 | morbid obesity | Inonu University | Completed | No outcome recorded |
| Phase 4 | NCT03265782 | Jun 2015 → Sep 2017 | patent ductus arteriosus | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT03568721 | Jan 2015 → Mar 2018 | — | Rio de Janeiro State University | Completed | No outcome recorded |
| Phase 4 | NCT02294071 | Dec 2014 → Nov 2015 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| Phase 4 | NCT02327338 | Nov 2014 → Feb 2015 | — | Future Sciene Technology | Completed | No outcome recorded |
| Phase 4 | NCT02296840 | Nov 2014 → Nov 2016 | drug allergy, obstructive sleep apnea syndrome, tonsillitis | Emory University | Terminated | No outcome recorded |
| Phase 4 | NCT02227316 | Aug 2014 → Sep 2016 | benign neoplasm of corpus uteri | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT02076321 | Jan 2014 → Nov 2016 | — | University of Missouri-Columbia | Completed | No outcome recorded |
| Phase 4 | NCT01901393 | Jul 2013 → Aug 2014 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01530880 | Oct 2012 → Mar 2016 | — | Columbia University | Terminated | No outcome recorded |
| Phase 4 | NCT01707251 | Oct 2012 → Mar 2015 | obesity disorder | Jacobi Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01563185 | Apr 2012 → Mar 2015 | juvenile idiopathic arthritis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT01488955 | Feb 2012 → Feb 2014 | urinary tract infection | Institute of Application-oriented Research and Clinical Trials GmbH | Completed | No outcome recorded |
| Phase 4 | NCT01514175 | Jan → Dec 2012 | chronic pain syndrome | Culpeper Surgery Center | Unknown | No outcome recorded |
| Phase 4 | NCT01377441 | Sep 2011 → May 2013 | inflammatory disease | NYU Langone Health | Terminated | No outcome recorded |
| Phase 4 | NCT01392378 | Aug 2011 → Jan 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT01334957 | Jun 2011 → Dec 2012 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01230411 | Jun 2011 → Jun 2017 | migraine disorder | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 4 | NCT01334944 | Jun 2011 → Sep 2012 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01235949 | Nov 2010 → Mar 2012 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01756209 | Jan 2010 → Feb 2012 | migraine without aura | University of Catanzaro | Completed | No outcome recorded |
| Phase 4 | NCT01066676 | Oct 2009 → Jun 2012 | osteoarthritis | Gebro Pharma GmbH | Completed | No outcome recorded |
| Phase 4 | NCT00961753 | Aug 2009 → Oct 2010 | patent ductus arteriosus | OSF Healthcare System | Terminated | No outcome recorded |
| Phase 4 | NCT00938509 | Jul → Oct 2009 | — | Soroka University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00921700 | Jun 2009 → Nov 2014 | neuropathy, painful | Ullevaal University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00484744 | Jun 2007 → Jan 2008 | — | University of Missouri, Kansas City | Completed | No outcome recorded |
| Phase 4 | NCT00470743 | May 2007 → Jun 2009 | patent ductus arteriosus | KK Women's and Children's Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT01966172 | Mar 2007 → Aug 2009 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT01359020 | Jan 2007 → Mar 2008 | — | Mantecorp Industria Quimica e Farmaceutica Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00317655 | Apr 2006 → Apr 2007 | — | Ferrosan AS | Completed | No outcome recorded |
| Phase 4 | NCT00382083 | Mar → Jun 2006 | breast disorder | Mountain States Tumor and Medical Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00267293 | Jan 2006 → Jun 2009 | — | Penn State University | Completed | No outcome recorded |
| Phase 4 | NCT00631514 | Jan 2005 → Sep 2006 | hypertensive disorder | University of Split | Completed | No outcome recorded |
| Phase 4 | NCT00217191 | Sep 2004 → Sep 2006 | patent ductus arteriosus, pulmonary immaturity | Maternite Regionale Universitaire | Completed | No outcome recorded |
| Phase 4 | NCT00167713 | Apr 2003 → Jan 2004 | — | Albert Schweitzer Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00565500 | Apr 2003 → Apr 2005 | ischemic disease, osteoarthritis | University of Chieti | Completed | No outcome recorded |
| Phase 4 | NCT00620867 | Oct 2002 → Mar 2003 | osteoarthritis, knee | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00046358 | Sep 2002 → Aug 2005 | Alzheimer disease | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT00145730 | Feb 2002 → May 2004 | osteoarthritis, hip, rheumatoid arthritis | The George Institute | Completed | No outcome recorded |
| Phase 4 | NCT00240864 | ? → Feb 2004 | — | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 4 | NCT00281762 | ? → Jan 2007 | — | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase 4 | NCT00240825 | ? → Feb 2004 | — | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase 4 | NCT00261586 | ? → Mar 2004 | — | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| Phase not applicable75 trials | ||||||
| — | NCT07435493 | Nov 2026 expected | adenoid hypertrophy, obstructive sleep apnea syndrome | Ain Shams University | Not yet recruiting | No outcome recorded |
| — | NCT07539961 | Sep 2026 → Dec 2027 expected | calcific tendinitis | University Hospital Dubrava | Not yet recruiting | No outcome recorded |
| — | NCT07610408 | Jun → Sep 2026 expected | — | Ankara Etlik City Hospital | Recruiting | No outcome recorded |
| — | NCT07399184 | Feb → Aug 2026 overdue | delirium | Ondokuz Mayıs University | Not yet recruiting | No outcome recorded |
| — | NCT07618494 | Feb → May 2026 | dental pulp disorder | Pakistan Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT07374354 | Feb 2026 overdue | — | October University for Modern Sciences and Arts | Recruiting | No outcome recorded |
| — | NCT06696573 | Dec 2024 → Dec 2025 overdue | habitual spontaneous abortion | Le Thi Kieu Trang | Recruiting | No outcome recorded |
| — | NCT06015165 | Sep 2024 → Jun 2025 overdue | — | China-Japan Friendship Hospital | Recruiting | No outcome recorded |
| — | NCT06453291 | Jul 2024 → Apr 2025 overdue | chronic pain syndrome | Iffat Anwar Medical Complex | Recruiting | No outcome recorded |
| — | NCT06937853 | May 2024 → Jul 2025 overdue | — | Ataturk University | Recruiting | No outcome recorded |
| — | NCT06601114 | Apr → Oct 2024 overdue | patent ductus arteriosus | Arooj Khan | Active not recruiting | No outcome recorded |
| — | NCT07125911 | Apr 2024 → Apr 2025 | periapical periodontitis | HITEC-Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT06594224 | Mar → Aug 2024 | — | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT05983354 | Jan → Jun 2024 | migraine disorder | Health Sciences North Research Institute | Unknown | No outcome recorded |
| — | NCT06174363 | Dec 2023 → Dec 2025 overdue | breast cancer | Yonsei University | Recruiting | No outcome recorded |
| — | NCT06015711 | Aug 2023 → Aug 2026 overdue | substance-related disorder | Ajou University School of Medicine | Recruiting | No outcome recorded |
| — | NCT05685342 | Feb 2023 → Feb 2025 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT06188143 | Dec 2022 → Jun 2023 | — | Phramongkutklao College of Medicine and Hospital | Completed | No outcome recorded |
| — | NCT05626010 | Nov 2022 → Oct 2023 | thyroid gland disorder | The Catholic University of Korea | Unknown | No outcome recorded |
| — | NCT05366777 | Oct 2022 → Jul 2023 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT05509244 | Sep 2022 → Aug 2023 | female reproductive system disorder | The Catholic University of Korea | Unknown | No outcome recorded |
| — | NCT05878262 | Sep 2022 → Mar 2023 | ankyloglossia, teeth, supernumerary | The Children's Hospital of Zhejiang University School of Medicine | Completed | No outcome recorded |
| — | NCT05248152 | Jan 2022 → Jan 2024 | — | University Medical Centre Ljubljana | Unknown | No outcome recorded |
| — | NCT06574516 | Nov 2021 → Aug 2022 | — | King Abdullah University Hospital | Completed | No outcome recorded |
| — | NCT05053009 | Nov 2021 → Oct 2022 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT04653506 | Nov 2020 → Jul 2022 | — | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| — | NCT03868137 | Sep 2020 → May 2022 | pelvis syndrome | Orlando VA Medical Center | Unknown | No outcome recorded |
| — | NCT04523623 | Jul 2020 → Jun 2021 | childhood acute lymphoblastic leukemia | Washington University School of Medicine | Withdrawn | No outcome recorded |
| — | NCT04087317 | Jun 2020 → Jun 2022 | postpartum depression, substance-related disorder | Rambam Health Care Campus | Completed | No outcome recorded |
| — | NCT06291337 | Jun 2020 → Sep 2023 | — | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| — | NCT04382768 | May 2020 → Jan 2021 | COVID-19, severe acute respiratory syndrome | Química Luar SRL | Unknown | No outcome recorded |
| — | NCT04337814 | Dec 2019 → Jun 2022 | — | Aga Khan University Hospital, Pakistan | Completed | No outcome recorded |
| — | NCT04202224 | Oct 2018 → Feb 2019 | — | Lithuanian University of Health Sciences | Completed | No outcome recorded |
| — | NCT03952715 | Apr 2018 → Jul 2019 | — | University of Haifa | Unknown | No outcome recorded |
| — | NCT03423329 | Jan → Apr 2018 | — | Ain Shams University | Completed | No outcome recorded |
| — | NCT03658720 | Dec 2017 | — | Reckitt Benckiser Healthcare (UK) Limited | Terminated | No outcome recorded |
| — | NCT03352362 | Dec 2017 → Mar 2019 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT03146689 | Aug 2017 → Oct 2018 | osteoarthritis, knee | University of Nottingham | Completed | No outcome recorded |
| — | NCT03518463 | Jun → Jul 2017 | pregnancy disorder | Mbarara University of Science and Technology | Completed | No outcome recorded |
| — | NCT02603848 | Feb 2017 → Feb 2024 | — | McMaster University | Unknown | No outcome recorded |
| — | NCT03011567 | Jan 2017 → Oct 2019 | hypertension, pregnancy-induced | MemorialCare Health System | Completed | No outcome recorded |
| — | NCT02935894 | Nov 2016 → Jun 2017 | — | USDA, Western Human Nutrition Research Center | Completed | No outcome recorded |
| — | NCT02807623 | Sep 2016 → Dec 2018 | immune system disorder | Womack Army Medical Center | Completed | No outcome recorded |
| — | NCT02745925 | Apr 2016 → Dec 2018 | obesity disorder | Swiss Federal Institute of Technology | Completed | No outcome recorded |
| — | NCT05256147 | Aug 2015 → May 2016 | vitiligo | Henry Ford Health System | Terminated | No outcome recorded |
| — | NCT02863614 | May 2015 → May 2017 | infertility disorder | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT02806869 | Jan 2015 → Nov 2016 | — | University of Michigan | Completed | No outcome recorded |
| — | NCT02327234 | Dec 2014 → Apr 2015 | allergic asthma | University of Saskatchewan | Completed | No outcome recorded |
| — | NCT02219698 | Jul 2014 → Jul 2015 | diverticulitis | Helsinki University Central Hospital | Completed | No outcome recorded |
| — | NCT02140970 | May 2014 → Jan 2020 | ureteral obstruction, urolithiasis | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT01982799 | Feb 2014 → Sep 2015 | tooth disorder | University of Minnesota | Withdrawn | No outcome recorded |
| — | NCT04227652 | Sep 2013 → Feb 2019 | infectious disease with sepsis | University Hospital Ostrava | Completed | No outcome recorded |
| — | NCT02064894 | Jul 2013 → Jun 2015 | musculoskeletal system disorder | St. Justine's Hospital | Completed | No outcome recorded |
| — | NCT01886196 | Apr 2013 → Jul 2014 | muscular atrophy, osteoporosis | University of Saskatchewan | Completed | No outcome recorded |
| — | NCT01837810 | Apr 2013 → Apr 2016 | — | Brooke Army Medical Center | Unknown | No outcome recorded |
| — | NCT01666587 | Aug 2012 → Apr 2013 | ischemic disease | University of Essex | Completed | No outcome recorded |
| — | NCT01586299 | Mar 2012 → Jun 2015 | pleuropneumonia | Rabin Medical Center | Unknown | No outcome recorded |
| — | NCT00258791 | Jan → May 2012 | mental disorder | Norwegian University of Science and Technology | Withdrawn | No outcome recorded |
| — | NCT01400737 | Jul 2011 → Jul 2012 | — | Zekai Tahir Burak Women's Health Research and Education Hospital | Unknown | No outcome recorded |
| — | NCT01530217 | Mar → Apr 2011 | pulpitis | Universidade Estadual de Ponta Grossa | Completed | No outcome recorded |
| — | NCT01511887 | Jan → Dec 2011 | patent ductus arteriosus | Hormozgan University of Medical Sciences | Completed | No outcome recorded |
| — | NCT00530387 | Jul 2008 → Jul 2011 | photoallergic dermatitis | NHS Tayside | Completed | No outcome recorded |
| — | NCT00802685 | Nov 2007 → Aug 2010 | patent ductus arteriosus | University of Miami | Terminated | No outcome recorded |
| — | NCT00462722 | Jul 2007 → Dec 2011 | — | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT01758913 | Feb 2007 → Feb 2012 | patent ductus arteriosus | Taipei Medical University Hospital | Completed | No outcome recorded |
| — | NCT00567528 | May 2006 → Apr 2009 | — | Akron Children's Hospital | Terminated | No outcome recorded |
| — | NCT00389272 | Sep 2005 → Dec 2008 | — | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| — | NCT00239512 | Mar 2005 → Jun 2006 | patent ductus arteriosus | China Medical University Hospital | Terminated | No outcome recorded |
| — | NCT00245375 | Jan → Dec 2005 | gallbladder disorder | Nova Scotia Health Authority | Completed | No outcome recorded |
| — | NCT00219895 | Aug 2004 → Mar 2006 | cystic fibrosis | Ramsey, Bonnie, MD | Completed | No outcome recorded |
| — | NCT00646906 | Jun 2004 → Jan 2012 | arthritic joint disease, myocardial infarction | University of Pennsylvania | Completed | No outcome recorded |
| — | NCT00520442 | Sep 2003 → Sep 2007 | — | Medical College of Wisconsin | Completed | No outcome recorded |
| — | NCT00474721 | Nov 2002 → Feb 2004 | — | University of California, San Diego | Completed | No outcome recorded |
| — | NCT00004440 | Aug 1996 → Jun 1999 | cystic fibrosis | FDA Office of Orphan Products Development | Completed | No outcome recorded |
| — | NCT00002276 | — | HIV infectious disease, hemophilia A | University of Pittsburgh | Completed | No outcome recorded |
Also used as a comparator or background therapy in 412 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 010 trials | ||||||
| Phase 0 | NCT06640439 Background | Oct 2024 → Feb 2025 overdue | impacted teeth, multiple | Huashan Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07016451 Background | Apr 2024 → Sep 2025 | radiation cystitis | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 0 | NCT06212830 Comparator | Feb 2024 → Feb 2025 | — | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| Phase 0 | NCT07204379 Comparator | Jan → Jul 2023 | — | Armed Forces Institute of Dentistry, Pakistan | Completed | No outcome recorded |
| Phase 0 | NCT03822962 Comparator | Nov 2020 → May 2023 | opioid abuse, sinusitis | University of Nebraska | Terminated | No outcome recorded |
| Phase 0 | NCT04059172 Comparator | Dec 2019 → Jun 2028 expected | persistent idiopathic facial pain | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 0 | NCT04123717 Comparator | Oct 2019 → Mar 2024 | — | Hamad Medical Corporation | Completed | No outcome recorded |
| Phase 0 | NCT06484439 Comparator | Feb 2018 → Nov 2021 | impacted teeth, multiple, neuropathy, painful | United States Naval Medical Center, San Diego | Completed | No outcome recorded |
| Phase 0 | NCT02373254 Comparator | Jan → Oct 2015 | — | University of California, Davis | Completed | No outcome recorded |
| Phase 0 | NCT01972906 Comparator | Feb 2012 → Feb 2014 | primary dysmenorrhea | Chengdu University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 127 trials | ||||||
| Phase 1 | NCT05729555 Comparator | Apr → Oct 2023 | insomnia | Overseas Pharmaceuticals, Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04681105 Background | Nov 2020 → Aug 2025 | B-cell acute lymphoblastic leukemia, CD4+/CD56+ hematodermic neoplasm, Hodgkins lymphoma, T-cell acute lymphoblastic leukemia +4 | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT04424420 Comparator | Nov 2019 → Mar 2021 | — | Prof. Jürgen Brockmöller | Unknown | No outcome recorded |
| Phase 1 | NCT05428293 Comparator | Feb → Mar 2019 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT03640247 Comparator | Nov 2018 → Dec 2019 | parathyroid gland disorder, thyroid gland disorder | MetroHealth Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT03694587 Comparator | Sep → Oct 2018 | — | Medherant Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03648437 Background | Sep 2018 → Oct 2024 | patent ductus arteriosus | University of Oulu | Terminated | No outcome recorded |
| Phase 1 | NCT03385057 Comparator | Sep 2018 → Jan 2023 | — | Massachusetts Eye and Ear Infirmary | Withdrawn | No outcome recorded |
| Phase 1 | NCT04330547 Comparator | Feb 2018 → Feb 2019 | akinetic mutism, brain injury | University of Liege | Completed | No outcome recorded |
| Phase 1 | NCT03154645 Comparator | Aug → Oct 2017 | acute mountain sickness | Grant S Lipman | Completed | No outcome recorded |
| Phase 1 | NCT02973958 Background | Feb 2017 → Jun 2018 | balanitis, neuropathy, painful, paraphimosis | Alberta Children's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02974361 Comparator | Dec 2016 → Apr 2017 | — | Oxford Pharmascience Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02629354 Comparator | Nov 2015 → Jan 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02349607 Comparator | Jan → Mar 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02260947 Comparator | Oct → Dec 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02256423 Comparator | Jul → Aug 2014 | — | Simbec Research | Completed | No outcome recorded |
| Phase 1 | NCT02050958 Comparator | Feb → Mar 2014 | — | Oxford Pharmascience Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02452450 Comparator | Jan → Oct 2014 | — | Reckitt Benckiser Healthcare (UK) Limited | Completed | No outcome recorded |
| Phase 1 | NCT01879371 Comparator | Jun → Jul 2013 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02096913 Comparator | Jun 2013 → Sep 2017 | spinal cord injury | Jan M. Schwab, MD, PhD | Completed | No outcome recorded |
| Phase 1 | NCT01555476 Comparator | Feb → Mar 2012 | — | McNeil AB | Completed | No outcome recorded |
| Phase 1 | NCT01478022 Comparator | Oct 2011 → Mar 2016 | Duchenne muscular dystrophy | Parent Project, Italy | Completed | No outcome recorded |
| Phase 1 | NCT01097902 Comparator | Feb → Sep 2010 | — | Martin Angst | Completed | No outcome recorded |
| Phase 1 | NCT00962663 Comparator | Aug → Dec 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00662896 Comparator | Mar → Sep 2008 | essential hypertension, osteoarthritis | NicOx | Completed | No outcome recorded |
| Phase 1 | NCT00565084 Comparator | Mar → Dec 2007 | osteoarthritis, knee | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02183012 Comparator | Aug → Oct 2002 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT04990388 Background | Oct 2021 → Mar 2023 | glycogen storage disease III | Ultragenyx Pharmaceutical Inc | Terminated | No outcome recorded |
| Phase 1/2 | NCT04791761 Background | Apr 2021 → Jul 2023 | adenoid hypertrophy, substance-related disorder | David Chi, MD | Terminated | No outcome recorded |
| Phase 1/2 | NCT04432597 Background | Aug 2020 → Nov 2022 overdue | anal carcinoma, cervical cancer, oropharynx cancer, virus associated tumor | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03952650 Background | May 2019 → Feb 2021 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/2 | NCT03618823 Background | Oct 2018 → May 2020 | adenoid hypertrophy | David Chi, MD | Terminated | No outcome recorded |
| Phase 1/2 | NCT03493945 Background | May 2018 → Oct 2024 | castration-resistant prostate carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01149564 Comparator | Dec 2009 → Jun 2012 | patent ductus arteriosus | China Medical University Hospital | Unknown | No outcome recorded |
| Phase 253 trials | ||||||
| Phase 2 | NCT07094542 Comparator | Sep 2026 → Nov 2029 expected | impacted teeth, multiple, myofascial pain syndrome | Rutgers, The State University of New Jersey | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07487246 Comparator | Jun 2026 → Apr 2027 expected | — | Rush University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06496854 Background | Oct 2025 → Jan 2026 | — | University of Wisconsin, Madison | Withdrawn | No outcome recorded |
| Phase 2 | NCT06911359 Comparator | Mar 2025 → Dec 2026 expected | osteoarthritis, knee | David Grant U.S. Air Force Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06980870 Comparator | Feb → Jun 2025 overdue | — | Armed Forces Institute of Dentistry, Pakistan | Recruiting | No outcome recorded |
| Phase 2 | NCT07143201 Comparator | Jul 2024 → Jul 2026 overdue | patent ductus arteriosus | Hamilton Health Sciences Corporation | Recruiting | No outcome recorded |
| Phase 2 | NCT06214273 Comparator | Apr → Jul 2024 | chemotherapy-induced oral mucositis | Cairo University | Unknown | No outcome recorded |
| Phase 2 | NCT05750264 Comparator | Mar 2023 → Dec 2025 overdue | — | Menoufia University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05340582 Background | Dec 2022 → Jan 2027 expected | patent ductus arteriosus | Mount Sinai Hospital, Canada | Recruiting | No outcome recorded |
| Phase 2 | NCT04646967 Background | Nov 2022 → Jan 2024 | balanitis, neuropathy, painful, paraphimosis | Alberta Children's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04637529 Comparator | Aug 2022 → Jun 2023 | osteoarthritis | Apsen Farmaceutica S.A. | Completed | No outcome recorded |
| Phase 2 | NCT05971186 Comparator | Jun → Aug 2022 | primary dysmenorrhea | Padjadjaran University | Completed | No outcome recorded |
| Phase 2 | NCT05012098 Background | Jun 2022 → Jul 2024 | esthesioneuroblastoma, nasal cavity neoplasm, olfactory neuroblastoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT05493540 Comparator | Apr 2021 → Aug 2022 | patent ductus arteriosus | Nada Youssef | Completed | No outcome recorded |
| Phase 2 | NCT04026464 Comparator | Apr → May 2021 | patent ductus arteriosus | University of Florida | Withdrawn | No outcome recorded |
| Phase 2 | NCT03456817 Background | Jul 2020 → May 2025 | graft versus host disease | AHS Cancer Control Alberta | Terminated | No outcome recorded |
| Phase 2 | NCT03584152 Comparator | Aug 2019 → Nov 2024 | neuropathy, painful | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT03955211 Background | Jun 2019 → Dec 2021 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03865147 Background | Jan → Jul 2019 | — | Medical Ethics UK Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT03701074 Background | Dec 2018 → Oct 2020 | bronchopulmonary dysplasia, patent ductus arteriosus | University of South Alabama | Terminated | No outcome recorded |
| Phase 2 | NCT03695367 Background | Oct → Nov 2018 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03588910 Background | Aug 2018 → Jul 2019 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03691818 Comparator | Jul 2018 → Oct 2019 | osteoarthritis, knee | Tianjin XinChen-Techfields Pharma Co., LTD. | Completed | No outcome recorded |
| Phase 2 | NCT03088800 Comparator | Apr 2018 → Oct 2019 | — | Antonios Likourezos | Completed | No outcome recorded |
| Phase 2 | NCT03173456 Comparator | Nov 2017 → Nov 2019 | musculoskeletal system disorder | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT03241030 Background | Sep 2017 → Jul 2018 | hand, foot and mouth disease, herpangina, stomatitis | University of Texas at Austin | Completed | No outcome recorded |
| Phase 2 | NCT03223519 Comparator | Jul → Nov 2017 | — | Spherium Biomed | Completed | No outcome recorded |
| Phase 2 | NCT03111186 Comparator | Apr 2017 → May 2019 | carpal tunnel syndrome, de Quervain disease, ganglion or cyst of synovium/tendon/bursa, palmar fibromatosis | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT02422966 Comparator | Dec 2015 → Jan 2019 | patent ductus arteriosus | Angelini Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02521415 Background | Dec 2015 → Nov 2016 | disease of bone structure | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02602054 Comparator | Oct 2015 → Apr 2016 | patent ductus arteriosus | Hospital General Naval de Alta Especialidad - Escuela Medico Naval | Unknown | No outcome recorded |
| Phase 2 | NCT02276911 Comparator | Mar 2015 → Jun 2017 | spondylosis, spondylosis, cervical | St. Joseph's Hospital and Medical Center, Phoenix | Terminated | No outcome recorded |
| Phase 2 | NCT02320708 Comparator | Dec 2014 → Apr 2015 | — | Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02128191 Comparator | Jul 2014 → Aug 2019 | bronchopulmonary dysplasia | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01932554 Background | Nov 2013 → Mar 2015 | sickle cell disease | St. Louis University | Withdrawn | No outcome recorded |
| Phase 2 | NCT01900795 Comparator | Jul → Nov 2013 | — | Purdue Pharma LP | Terminated | No outcome recorded |
| Phase 2 | NCT01785108 Comparator | Feb 2013 → Mar 2017 | type 1 diabetes mellitus | Johnny Ludvigsson | Completed | No outcome recorded |
| Phase 2 | NCT01670656 Background | Jan → Sep 2013 | dysmenorrhea | Organon and Co | Completed | No outcome recorded |
| Phase 2 | NCT01686802 Comparator | Sep 2012 → Sep 2016 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 2 | NCT01529346 Comparator | Dec 2011 → Jun 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01512160 Comparator | Oct 2011 → Mar 2012 | — | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT01307020 Comparator | Feb → Oct 2011 | — | Menarini Group | Completed | No outcome recorded |
| Phase 2 | NCT01238120 Comparator | Nov 2010 → Dec 2019 | — | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT01827475 Comparator | Jul 2010 → Jul 2011 | — | Stony Brook University | Completed | No outcome recorded |
| Phase 2 | NCT01429935 Comparator | Jun 2010 → Sep 2011 | impacted teeth, multiple | Qazvin University Of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT00986882 Comparator | Sep 2009 → Mar 2011 | — | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00945763 Comparator | Jul → Nov 2009 | — | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00993863 Comparator | Jun → Sep 2007 | — | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00790270 Comparator | Jan 2003 → Jan 2004 | — | Stony Brook University | Completed | No outcome recorded |
| Phase 2 | NCT02183051 Comparator | Apr → Oct 1998 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02187588 Comparator | Feb 1998 → May 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00954200 Comparator | ? → Jan 2015 | — | Shaare Zedek Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01104844 Comparator | — | dental pulp disorder | AFT Pharmaceuticals, Ltd. | Withdrawn | No outcome recorded |
| Phase 2/310 trials | ||||||
| Phase 2/3 | NCT06006663 Comparator | Aug → Oct 2023 | — | Tanta University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05871086 Background | May → Dec 2023 | juvenile idiopathic arthritis | Nourhan Elsherif | Unknown | No outcome recorded |
| Phase 2/3 | NCT04986839 Comparator | Sep 2021 → Dec 2023 | patent ductus arteriosus | Manchester University NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 2/3 | NCT06231212 Comparator | Aug 2020 → Sep 2021 | temporomandibular joint disorder | Chulalongkorn University | Completed | No outcome recorded |
| Phase 2/3 | NCT03509675 Comparator | Apr 2018 → Jan 2019 | lichen planus, oral | University of Washington | Completed | No outcome recorded |
| Phase 2/3 | NCT02056223 Comparator | Jan 2017 → Oct 2019 | patent ductus arteriosus, respiratory distress syndrome in premature infants | University of Padova | Suspended | No outcome recorded |
| Phase 2/3 | NCT02593721 Comparator | Jul → Sep 2015 | peripheral neuropathy | Universidad Europea de Madrid | Completed | No outcome recorded |
| Phase 2/3 | NCT02507219 Comparator | Jul → Oct 2015 | major depressive disorder | Laureate Institute for Brain Research, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT01973010 Comparator | Jun 2013 → May 2014 | — | Chengdu University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 2/3 | NCT01755702 Comparator | Jul 2009 → Mar 2010 | headache disorder | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 358 trials | ||||||
| Phase 3 | NCT07145645 Comparator | Apr 2026 → Sep 2027 expected | musculoskeletal system disorder | University of Calgary | Recruiting | No outcome recorded |
| Phase 3 | NCT07146997 Comparator | Nov 2023 → Nov 2024 | pulpitis | Zahoor khan | Completed | No outcome recorded |
| Phase 3 | NCT06948513 Comparator | Dec 2022 → Jun 2023 | — | Zitelli & Brodland Skin Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT05484401 Comparator | Aug 2022 → Jun 2023 | impacted teeth, multiple, tooth disorder | Reckitt Benckiser Healthcare (UK) Limited | Completed | No outcome recorded |
| Phase 3 | NCT05632133 Background | Jun 2022 → Aug 2023 | migraine disorder | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 3 | NCT05630222 Comparator | Mar 2022 → Feb 2023 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT05318521 Comparator | Dec 2021 → Aug 2022 | osteoarthritis, knee | Overseas Pharmaceuticals, Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04879823 Background | Aug 2021 → Jul 2023 | — | David Chi, MD | Terminated | No outcome recorded |
| Phase 3 | NCT07006675 Comparator | May 2021 → Dec 2026 expected | — | Major Extremity Trauma Research Consortium | Recruiting | No outcome recorded |
| Phase 3 | NCT04452344 Comparator | Jan 2021 → Jul 2023 overdue | substance-related disorder | Rutgers, The State University of New Jersey | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04551196 Comparator | Sep 2020 → Nov 2022 | tonsillitis | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT05283499 Comparator | Jul 2020 → Mar 2021 | — | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 3 | NCT04423107 Comparator | Jul 2020 → Jun 2022 | hypospadias | University of Oklahoma | Unknown | No outcome recorded |
| Phase 3 | NCT04271917 Comparator | Feb 2020 → Mar 2022 | — | University of Tennessee | Completed | No outcome recorded |
| Phase 3 | NCT04133623 Comparator | Nov 2019 → Sep 2021 | — | IRCCS Burlo Garofolo | Completed | No outcome recorded |
| Phase 3 | NCT03929640 Comparator | Aug 2019 → Mar 2020 | substance-related disorder | Milton S. Hershey Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT03974932 Background | Jun 2019 → Dec 2020 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT03692416 Comparator | Nov 2018 → Nov 2021 | vasculitis | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT03571737 Background | Jun 2018 → Dec 2020 | musculoskeletal system disorder | East Carolina University | Completed | No outcome recorded |
| Phase 3 | NCT03404518 Comparator | Feb → Oct 2018 | — | Loma Linda University | Completed | No outcome recorded |
| Phase 3 | NCT02863575 Comparator | Oct 2017 → Apr 2018 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT03224403 Comparator | Jul 2017 → Apr 2018 | — | Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division | Completed | No outcome recorded |
| Phase 3 | NCT04037514 Comparator | Jul 2017 → Dec 2024 | patent ductus arteriosus | Máximo Vento Torres | Completed | No outcome recorded |
| Phase 3 | NCT02761980 Comparator | Dec 2016 → Dec 2017 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT03534869 Comparator | Nov 2016 → Apr 2017 | — | University Hospital Sestre Milosrdnice | Completed | No outcome recorded |
| Phase 3 | NCT02689063 Comparator | Oct 2016 → Jun 2017 | — | AFT Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02837952 Comparator | Aug 2016 → Feb 2017 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02735122 Comparator | Apr → Oct 2016 | — | Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division | Completed | No outcome recorded |
| Phase 3 | NCT03022253 Background | Mar 2016 → Mar 2017 | patent ductus arteriosus | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 3 | NCT02668783 Background | Feb → Sep 2016 | primary dysmenorrhea | Organon and Co | Terminated | No outcome recorded |
| Phase 3 | NCT02668822 Background | Feb → Sep 2016 | primary dysmenorrhea | Organon and Co | Terminated | No outcome recorded |
| Phase 3 | NCT02547818 Comparator | Sep 2015 → Nov 2020 | Alzheimer disease | AZTherapies, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02912650 Comparator | Sep 2015 → Jun 2016 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02480114 Background | Jul 2015 → Sep 2019 | head and neck cancer, mucositis, radiation-induced disorder | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT02476422 Comparator | Apr → Aug 2015 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02272725 Comparator | Mar 2015 → Mar 2016 | acute kidney injury, water intoxication | Stanford University | Completed | No outcome recorded |
| Phase 3 | NCT02732808 Background | Sep 2014 → Apr 2016 | female infertility | Royan Institute | Completed | No outcome recorded |
| Phase 3 | NCT02007434 Background | Dec 2013 → Jun 2014 | — | Kythera Biopharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01874626 Comparator | Jun 2013 → Jan 2014 | — | Strategic Science & Technologies, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01842633 Comparator | Apr 2013 → Mar 2015 | — | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 3 | NCT01420653 Comparator | Apr 2013 → Dec 2014 | — | AFT Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01755728 Comparator | Jan 2013 → Dec 2018 | patent ductus arteriosus | Hillel Yaffe Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01567072 Comparator | Apr 2012 → Jun 2016 | — | Marius Aliuskevicius | Completed | No outcome recorded |
| Phase 3 | NCT01373697 Comparator | Jun → Aug 2011 | muscular atrophy, tendinitis | Laboratório Teuto Brasileiro S/A | Unknown | No outcome recorded |
| Phase 3 | NCT01297829 Comparator | Feb 2011 → Aug 2013 | — | St. Barnabas Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT01171794 Comparator | Jul → Aug 2010 | altitude sickness | Stanford University | Completed | No outcome recorded |
| Phase 3 | NCT01077973 Comparator | Mar → Oct 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00820027 Comparator | Dec 2008 → Dec 2010 | neuropathy, painful | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00792818 Comparator | Dec 2008 → Oct 2012 | osteoarthritis | Mahidol University | Completed | No outcome recorded |
| Phase 3 | NCT00694369 Comparator | Jun → Dec 2008 | — | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00812422 Comparator | Feb 2008 → May 2009 | respiratory tract infectious disorder | Inje University | Completed | No outcome recorded |
| Phase 3 | NCT00613106 Comparator | Sep 2007 → Oct 2008 | complex regional pain syndrome, osteoarthritis, rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00619307 Comparator | Jul 2007 → Apr 2008 | multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT00450658 Comparator | Mar 2007 → Sep 2008 | peptic ulcer disease | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00299039 Comparator | May 2006 → Jun 2008 | breast disorder | Nova Scotia Health Authority | Completed | No outcome recorded |
| Phase 3 | NCT01028079 Comparator | Nov 2005 → Dec 2006 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00225732 Comparator | Jan 2005 → Jan 2008 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01420666 Comparator | — | osteoarthritis | AFT Pharmaceuticals, Ltd. | Withdrawn | No outcome recorded |
| Phase 4127 trials | ||||||
| Phase 4 | NCT07625267 Background | Jul 2026 → Jun 2028 expected | diverticulitis of colon | Montefiore Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07600697 Background | Jul 2026 → Jul 2027 expected | female stress incontinence, pelvic organ prolapse | University of California, Los Angeles | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07527039 Background | Apr 2026 → May 2028 expected | hypertrophy of breast | Carilion Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT06935331 Background | Oct 2025 → Dec 2026 expected | adolescent idiopathic scoliosis | OrthoCarolina Research Institute, Inc. | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07393503 Comparator | Sep 2025 → Aug 2026 overdue | musculoskeletal system disorder | State University of New York at Buffalo | Enrolling by invitation | No outcome recorded |
| Show all 127 trials opens the full record — a long page | ||||||
| Phase not applicable120 trials | ||||||
| — | NCT07638644 Comparator | Jul 2026 → Feb 2027 expected | malposition of teeth with or without hypodontia/oligodontia | Bahria University | Not yet recruiting | No outcome recorded |
| — | NCT07620665 Comparator | Jun 2026 → May 2028 expected | — | Gangnam Severance Hospital | Recruiting | No outcome recorded |
| — | NCT07573137 Comparator | May → Oct 2026 expected | temporomandibular joint disorder | Khyber College of dentistry | Not yet recruiting | No outcome recorded |
| — | NCT07534488 Comparator | Apr → Jun 2026 overdue | pilonidal sinus | Medipol University | Not yet recruiting | No outcome recorded |
| — | NCT07493226 Comparator | Apr 2026 → Feb 2027 expected | frozen shoulder, neuropathy, painful | Konya Beyhekim Training and Research Hospital | Recruiting | No outcome recorded |
| Show all 120 trials opens the full record — a long page | ||||||
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-11-13 | Pfizer | Landmark Study Demonstrates Pfizer’s Celebrex (Celecoxib)Has Similar Cardiovascular Risk As Compared To Prescription Doses Of Ibuprofen and Naproxen pfizer.com ↗ |
Evidence & citations 67 cited values
Every value below carries the sentence it was read from. 785 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ibuprofen | “HZT-501, a fixed-dose combination of ibuprofen, a pain and inflammation relieving non-steroidal anti-inflammatory drug (NSAID), and famotidine, a histamine type 2 receptor...” NCT00984815 ↗752“When one or two dominant follicles (18 mm in diameter) observed, the final stage of oocyte maturation will be induced with triptorelin 100 μg (Decapeptyl®; Ferring GmbH,...” NCT02732808 ↗ “The primary objective was to investigate the efficiency of protective analgesia using combined effects of sustained release ibuprofen and bupivacaine nerve block in attenuation...” NCT00895843 ↗ “Opioid-Free Multimodal Analgesia will receive preoperative acetaminophen (15 mg/kg) and ibuprofen (10 mg/kg), intraoperative ketamine (0.5 mg/kg IV) and dexamethasone (0.1...” NCT07435493 ↗ “Participants were handed Brufen (Ibuprofen) (Abbott chemical laboratories, Advil, USA) 600 mg 3 times daily for 3 days after meals in tightly sealed envelope with an included...” NCT05479747 ↗ “IV indomethacin 2 mg/kg/dose for three doses at 12 hour intervals; or IV Ibuprofen 10 mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals...” NCT01291654 ↗ “All participants in the two groups will receive pharmacological treatment in the form of ibuprofen 400 mg, three times per day, during the first 2 days of menstruation, for 3...” NCT06987838 ↗ “During first 48 hours after surgery all patients wil receive paracetamol 15 mg/kg iv every 8 hours and ibuprofen 10 mg/kg orally (or through gastric tube) every 12 hours after surgery.” NCT04294537 ↗ “Subjects randomized to receive Ibuprofen will receive placebo to ICA-105665 at all scheduled dosing times on Days 1 to 4 and a single dose of 800 mg Ibuprofen on the morning of Day 4.” NCT00962663 ↗ “SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.” NCT02339129 ↗ “SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.” NCT02597634 ↗ “Both groups will receive intravenous 400 mg ibuprofen and 100 mg tramadol 20 minutes before the end of the surgery, and routine 1000 mg paracetamol every 8 hours postoperatively” NCT07534488 ↗ “800 milligrams of intravenous ibuprofen (patients greater 12 years of age) or 10 milligrams/kilograms (patients greater than 12 years; maximum of 400 milligrams) every 6 hours” NCT00606489 ↗ “Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.” NCT06604598 ↗ “A Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years” NCT07632274 ↗ “During this 3-month study, two antihypertensives, lisinopril/hydrochlorothiazide and amlodipine, were compared with three NSAIDs: ibuprofen, acetaminophen, and piroxicam.” PMID 18953082 ↗ Oct 2008 “Objective: To evaluate the postoperative analgesic effectiveness of meloxicam (7.5 mg) compared to ibuprofen (400 mg) in patients undergoing third molar(s) extraction.” NCT06704113 ↗ “The role of prostaglandin E2 is the permeability of the conduit, by which is indicated the use of cyclooxygenase inhibitors for closure (indomethacin and ibuprofen).” NCT02602054 ↗ “Ibuprofen((Fenbid, Tianjin Shike Pharmaceutical Co., Ltd)will be chosen as acute treatment, but no more than 10 times per month to avoid medication overuse headache.” NCT06322407 ↗ “The effect of ibuprofen, 600 mg thrice daily, was measured during fasting in a randomized, placebo-controlled, double-blinded crossover study of 17 healthy humans.” PMID 21029429 ↗ Oct 2010 “Participants were randomized to receive 5 mg of hydrocodone with 300 mg of acetaminophen (opioid) or 400 mg of ibuprofen and 500 mg of acetaminophen (nonopioid).” PMID 39755971 ↗ Jan 2025 “Ibuprofen 10 milligrams(mg)/kilogram (kg) (maximum 600mg) by mouth every 6 hours around the clock for 2 days, then as needed for pain thereafter (40 doses)” NCT06671002 ↗ “All the three groups will receive 400mg of Non-steroidal Anti-Inflammatory Drugs (Ibuprofen) once a day on the treatment days two hours before the session.” NCT06891976 ↗ “Current standard care includes the use of oral ibuprofen (IBU), a non-steroidal anti-inflammatory drug (NSAID), for mild-to-moderate MSK-I pain in the ED.” NCT02985177 ↗ “The regimen includes Paracetamol (oral or intravenous) 1g/24 hour, Ibuprofen IV 1200 mg/24 hour, or Parecoxib 80 mg/24 hour IV, and Tramadol 100 mg IV.” NCT07139691 ↗ “Patients are advised to take 1000 mg of acetaminophen every 6 hours and 600 mg of ibuprofen every 6 hours both scheduled and staggered 3 hours apart.” NCT07527039 ↗ “The intervention will involve the use of a generic NSAID (e.g., Ibuprofen), administered in oral tablet form at a specified dosage, such as 400 mg.” NCT06696573 ↗ “Intravenous 0.5 mg/kg tramadol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure.” NCT05566561 ↗ “combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids” NCT04010266 ↗ “fixed interval dosing of ibuprofen 600 mg along with acetaminophen 325 mg taken every 6 hours for the first 72 hours post-procedure” NCT07094542 ↗ “paracetamol 500 mg/ibuprofen 150 mg FDC, film-coated tablets. Two tablets 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).” NCT05222724 ↗ “oral pain medication in patients younger than 70 years: Ibuprofen 400mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)” NCT04685291 ↗ “Patients will be given Ibuprofen 600mg every 12 hours for pain relief following surgery at least for first three days as needed.” NCT02054676 ↗ “Patients randomized into this group (n=40) will, again by simple randomization, be given oral tablets of ibuprofen or naproxen” NCT07493226 ↗ “Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain.” NCT01628367 ↗ “NSAIDS (Ibuprofen or Aspirin) or Glucocorticoid (Prednisone) therapy for 3 weeks with addional colchicine therapy for 3 months” NCT04323280 ↗ “Ibuprofen pills, identical to the intervention (dipyrone pills), will be administered every 6 hour for a maximum of five days” NCT05586373 ↗ “Twenty-two participants were allocated 5% ibuprofen gel (A) and 0.025% capsaicin cream (B) in random sequence (AB or BA).” PMID 33197270 ↗ May 2021 “Nonsteroidal anti-inflammatory (NSAID; ibuprofen) and anti-emetic (metoclopramide) medication could be added as needed.” NCT00910689 ↗ “Maxigesic® is a combination of acetaminophen and ibuprofen, and is a drug that rapidly relieves various types of pain.” NCT06015711 ↗ “one vial of Maxigesic (acetaminophen 1000mg/ ibuprofen 300mg) is administered 15 minutes before the end of the surgery” NCT06174363 ↗ “Alternating Acetaminophen 975mg and Ibuprofen 600mg every 4 hours, with rescue Oxycodone 5mg every 4 hours, as needed” NCT07076069 ↗ “Ibuprofen: PO tablet with standard dosages of 200 mg, 400 mg, 600 mg, and 800 mg; treatment dosage of 200 to 800 mg” NCT07127107 ↗ “The study drug Caldolor® is an intravenous formulation of ibuprofen which was approved by the FDA in June 2009.” NCT02133326 ↗ “oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg)” NCT01011634 ↗ “Ibuprofen 2 months treatment: 2 tablets during 4 weeks (800 mg daily) + 1 tablet during 4 weeks (400 mg daily)” NCT04575519 ↗ “Triple combination of Ibuprofen, Magnesium and Vitamin C Powder for oral solution administered TID for 3 days” NCT03223519 ↗ “Participants will note the usual analgesic self-medication used to relief pain (ibuprofen, acetaminophen...).” NCT04164823 ↗ “Ibuprofen 5-10 mg/kg/dose every 6 hours; max 200 mg/dose; prescribe 56 doses (over the counter medication)” NCT04541147 ↗ “ibuprofen 0.3 g bid for 3 days, metronidazole 0.1 g tid, and cefaclor 0.375 g bid for 7 days after surgery” NCT06640439 ↗ “NSAIDs such as flurbiprofen axetil or ibuprofen will be administered as a complementary treatment option.” NCT06015165 ↗ “Ibuprofen PO dosed per body weight q 6-8 hours once toradol discontinued and discharged home with PO tabs” NCT06935331 ↗ “Effect of Ibuprofen Sustained Release on Intraoperative and Postoperative Pain in Mandibular Molars” NCT05053009 ↗ “NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.” NCT03881319 ↗ “Ibuprofen at 5.0 mg/kg and Acetaminophen at 15.0 mg/kg will be added to a Demerol-Vistaril regimen” NCT01971853 ↗ “patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid” NCT03060434 ↗ “Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.” NCT04189640 ↗ “The active ingredients of Combogesic® tablets are acetaminophen 325 mg and ibuprofen 97.5 mg.” NCT07225140 ↗ “Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.” NCT05972122 ↗ “Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.” NCT06866054 ↗ “Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.” NCT05972083 ↗ “Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.” NCT06546839 ↗ “Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.” NCT05476510 ↗ “One group will receive Ibuprofen for pain control and the other group will be given Tylenol.” NCT02902172 ↗ “Patients will be administered ibuprofen 400 mg IV every 8 hours in the postoperative period.” NCT07278050 ↗ “NSAID therapy (400 mg ibuprofen three times daily during menstruation) and routine follow-up” NCT07590232 ↗ “ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration” NCT01641289 ↗ “IV Acetaminophen 1g and ibuprofen 300mg will be provided q 8h until 24 h potperatively.” NCT07620665 ↗ “800 mg ibuprofen in 150 cc normal saline before operation will be given in 30 minutes.” NCT03170713 ↗ “* Ibuprofen 600 milligram (mg) by mouth every six hours as needed for pain (10 doses)” NCT05722002 ↗ “oral combination of paracetamol (500mg) - ibuprofen (400mg) will be given to group A” NCT06146491 ↗ “Indomethacin, ibuprofen or acetaminophen will be used as standard of care treatment” NCT01958320 ↗ “A single fixed dose combination of ibuprofen 400 mg and paracetamol 500 mg 8 hourly” NCT03518463 ↗ “NSAIDs like ibuprofen (600-800 mg) or declophenac sodium (50-150 mg) 3 times a day” NCT05422703 ↗ “Unheated wrap (sham) and oral ibuprofen were included for blinding purposes only.” PMID 25419887 ↗ Nov 2014 “Motrin - also known as ibuprofen 800 mg every 6 hours; not to exceed 3200 mg/day” NCT06113211 ↗ “Patients will be prescribed ibuprofen 600 mg three times per day for five days” NCT03524872 ↗ “acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion” NCT04005755 ↗ “24 Advil immediate-release (IR) caplets containing 200 mg Ibuprofen” NCT01383486 ↗ “1, Ibuprofen 400-mg and 1, Acetaminophen 500-mg capsule per dosage” NCT04676802 ↗ “Regular Tramadol, Metamizol, +/- Ibuprofen/Dexketorpofen/Parecoxib” NCT07604376 ↗ “double risk: ibuprofen, 200-400 mg per intake, plus lansoprazole” NCT05761015 ↗ “PO formulation: ibuprofen suspension 10mg/kg/dose, 400mg maximum” NCT06860711 ↗ “the patient receives 600mg of ibuprofen PO, also given standing” NCT03330119 ↗ “fixed-dose ibuprofen 250 mg / acetaminophen 500 mg formulation” NCT02837952 ↗ “NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam.” NCT04296422 ↗ “* Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg” NCT01734759 ↗ “Combination analgesic of ibuprofen 400mgacademinophen 350mg” NCT05283499 ↗ “Other NSAIDS (Naprosyn 500 mg BID or Ibuprofen 800 mg TID)” NCT04990804 ↗ “Daily oral medications: ibuprofen 400 mg three times a day” NCT04907864 ↗ “active ibuprofen 10% gel, 0.5cc to skin over injured area” NCT00567528 ↗ “ibuprofen 200mg/arginine 185mg twice per day for 8 weeks” NCT01414530 ↗ “* Ibuprofen - 30 to 40 mg/kg/day in 3 to 4 divided doses” NCT05871086 ↗ “NSAIDs: ibuprofen, celecoxib, or diclofenac/misoprostol” NCT01943435 ↗ “plus standard ibuprofen 600 mg every 8 hours for 5 days” NCT06603662 ↗ “200 mg of ibuprofen and 40 mg of caffeine anhydrous” NCT07204379 ↗ “standard oral NSAIDs (e.g., ibuprofen or celecoxib)” NCT07353372 ↗ “Ibuprofen (IBU) 200 mg/ Phenylephrine (PE) 10 mg” NCT01938144 ↗ “Medications: Ibuprofen, Naproxen, or Diclofenac.” NCT06453291 ↗ “800 mg Ibuprofen taken before dilator placement” NCT02354092 ↗ “Oral ibuprofen was given as first line therapy” NCT03534869 ↗ “treatment group 02 will ibuprofen (Alivium®).” NCT02409381 ↗ “5% Topical Ibuprofen (IBU) for Ankle Sprain” NCT01945034 ↗ “Ibuprofen 400 mg: 1 pill two times per day.” NCT07447024 ↗ “an antipyretic (ibuprofen or acetaminophen)” NCT03456817 ↗ “Group 1: Ibuprofen 400 mg (Abbott Brufen)” NCT07275710 ↗ “Ibuprofen 400mg for post-operative pain” NCT03457116 ↗ “Ibuprofen 400mg every 4 hours by mouth” NCT04704297 ↗ “ibuprofen 600mg + acetaminophen 325 mg” NCT01974609 ↗ “NSAIDs (e.g., Ibuprofen, Diclofenac)” NCT07016451 ↗ “Ibuprofen 800mg every 8 hours” NCT03640247 ↗ “Ibuprofen 5% topical gel BID” NCT01794923 ↗ “Ibuprofen Injection (IVIb)” NCT00867880 ↗ “Ibuprofen 800mg orally x 1” NCT05239767 ↗ “Group 3; Ibuprofen 400 mg” NCT03697746 ↗ “Ibuprofen 600 mg TID” NCT02269748 ↗ “Ibuprofen 5% gel” NCT01452997 ↗ “Drug: Ibuprofen” NCT06187584 ↗ “Ibuprofen 5 %” NCT00530387 ↗ “Ibuprofen” NCT00864357 ↗ “Ibuprofen” NCT04111315 ↗ “Ibuprofen” NCT02132416 ↗ “Ibuprofen” NCT01638962 ↗ “ibuprofen” NCT04990388 ↗ “Ibuprofen” NCT05332314 ↗ |
| Known as | Advil | “Currently, when a child has fever either ibuprofen (e.g. Motrin, Advil) or acetaminophen (e.g. Tylenol) is given.” NCT00267293 ↗11“oral analgesics for headache pain such as acetaminophen (Tylenol) or ibuprofen (Motrin or Advil).” NCT02443142 ↗ “Ibuprofen (also known as Advil or Motrin) is a medication that is known to reduce pain.” NCT01681667 ↗ “24 Advil immediate-release (IR) caplets containing 200 mg Ibuprofen” NCT01383486 ↗ “You may know ibuprofen by the name Advil or Motrin.” NCT01938040 ↗ “A2: Ibuprofen (Advil®, Pfizer S.A. de C.V.)” NCT05428293 ↗ “ibuprofen (also known as Motrin or Advil)” NCT04905563 ↗ “Pfizer 200 mg caplets (Advil)” NCT01716052 ↗ “Advil Ibuprofen table 200 mg” NCT03418805 ↗ “Ibuprofen (Advil)” NCT03404206 ↗ “Ibuprofen (Advil)” NCT07233733 ↗ |
| Known as | Advil Film Coated | “subjects were randomized 2:2:1 to receive a single oral dose of ibuprofen sodium tablets (Advil® Film Coated; 2 × 256 mg [equivalent to 400 mg standard ibuprofen]), standard...” PMID 26819724 ↗ Apr 2015 |
| Known as | Advil Ibuprofen Immediate-Release Tablet 200 mg | “Advil® Ibuprofen Immediate-Release Tablet 200 mg” NCT03418805 ↗ |
| Known as | Aktren | “one dose of Aktren® 200 mg überzogene Tabletten (Ibuprofen tablet)” NCT03694587 ↗ |
| Known as | Alivium | “treatment group 02 will ibuprofen (Alivium®).” NCT02409381 ↗ |
| Known as | ALZT-OP1b | “ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)” NCT04570644 ↗ |
| Known as | Brufen | “Participants were handed Brufen (Ibuprofen) (Abbott chemical laboratories, Advil, USA) 600 mg 3 times daily for 3 days after meals in tightly sealed envelope with an included...” NCT05479747 ↗7“The present study will be conducted in order to assess bioequivalence of the Test product (Ibuprofen 400 mg oral powder) and the Reference product 1 (Brufen 400 mg film-coated...” NCT03018015 ↗ “The study will compare the study drug to an already marketed formulation of prescription strength ibuprofen (Brufen® the reference product)” NCT02521207 ↗ “Group 1: Ibuprofen 400 mg (Abbott Brufen)” NCT07275710 ↗ “Drug: Ibuprofen (Brufen®)” NCT07316660 ↗ “Ibuprofen (Brufen®)” NCT01879371 ↗ “Ibuprofen (Brufen®)” NCT07512297 ↗ |
| Known as | Burana | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01535001 ↗ |
| Known as | Caldolor | “OBJECTIVES: To evaluate the efficacy of intravenous (IV) ibuprofen (Caldolor) administration in the management of acute pain in orthopedic trauma patients and to minimize opioid use.” PMID 31929374 ↗ Jul 20208“Caldolor® is an intravenous (IV) formulation of ibuprofen encompassing analgesic, anti-inflammatory and antipyretic (anti-fever) properties.” NCT01297829 ↗ “The aim of this study is to evaluate the preventive effect of intravenous ibuprofen (Caldolor®) on remifentanil-induced hyperalgesia” NCT02243254 ↗ “Ibuprofen 800 Mg in 8 mL INTRAVENOUS INJECTION [Caldolor]” NCT05763836 ↗ “ibuprofen (caldolor 10 mg / kg)” NCT03352362 ↗ |
| Known as | Dolormin | “Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.” NCT03180879 ↗ |
| Known as | Dolormin Extra | “400 mg ibuprofen (Dolormin Extra)” NCT03225352 ↗1“Dolormin® extra (Ibuprofen)” NCT02096913 ↗ |
| Known as | Fenbid | “Ibuprofen((Fenbid, Tianjin Shike Pharmaceutical Co., Ltd)will be chosen as acute treatment, but no more than 10 times per month to avoid medication overuse headache.” NCT06322407 ↗ |
| Known as | IBU | “A Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years” NCT07632274 ↗7“Current standard care includes the use of oral ibuprofen (IBU), a non-steroidal anti-inflammatory drug (NSAID), for mild-to-moderate MSK-I pain in the ED.” NCT02985177 ↗ “The investigators prefer to use Ibuprofen (IBU) for COX-inhibition in this study.” NCT02884219 ↗ “Ibuprofen (IBU) is an efficacious over-the-counter analgesic/antipyretic” PMID 25526232 ↗ Dec 2014 “Ibuprofen (IBU) 200 mg/ Phenylephrine (PE) 10 mg” NCT01938144 ↗ “5% Topical Ibuprofen (IBU) for Ankle Sprain” NCT01945034 ↗ “Commercial Ibuprofen (IBU) (400 mg)” NCT02320708 ↗ “Ibuprofen (IBU)” NCT04575519 ↗ |
| Known as | IBU sodium | “IBU sodium (IBU(Na)) is a newer, more soluble form that is absorbed faster than standard IBU, leading to more rapid analgesia.” PMID 25526232 ↗ Dec 2014 |
| Known as | IBU-H | “Ibuprofen (IBU-H), a widely used anti-inflammatory, also shows a marked antimicrobial effect” PMID 29772761 ↗ May 2018 |
| Known as | IBUCR | “Ibuprofen CR Tablets 600 mg (IBUCR)” NCT03418805 ↗ |
| Known as | Ibufen-L | “Ibuprofen (Ibufen-L® tablets 500 mg) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42).” NCT04111315 ↗ |
| Known as | Ibumetin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01606540 ↗ |
| Known as | IBUNa | “A novel, immediate-release tablet formulation of ibuprofen (IBU) sodium dihydrate, Advil Film Coated Tablets (IBUNa), has been developed” PMID 25119511 ↗ May 20151“IBU sodium (IBU(Na)) is a newer, more soluble form that is absorbed faster than standard IBU, leading to more rapid analgesia.” PMID 25526232 ↗ Dec 2014 |
| Known as | Ibuprofen (Advil) | “Ibuprofen (Advil)” NCT01605240 ↗ |
| Known as | ibuprofen (Brufen) | “ibuprofen (Brufen)” NCT04907864 ↗ |
| Known as | Ibuprofen (IBU) | “Ibuprofen (IBU)” NCT04575519 ↗ |
| Known as | Ibuprofen (Nurofen) | “Treatment order: Ibuprofen liquid capsules, Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen (Wockhardt)” NCT03497715 ↗ |
| Known as | Ibuprofen (Wockhardt) | “Treatment order: Ibuprofen liquid capsules, Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen (Wockhardt)” NCT03497715 ↗ |
| Known as | Ibuprofen 400 mg - Novapharin | “Ibuprofen 400 mg - Novapharin” NCT05971186 ↗ |
| Known as | Ibuprofen acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03658720 ↗ |
| Known as | Ibuprofen B.Braun | “Group A will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Ibuprofen B.Braun/Ibuprofen Kabi...” NCT07024199 ↗ |
| Known as | Ibuprofen Controlled-Release Tablet 600 mg | “Ibuprofen Controlled-Release Tablet 600 mg” NCT03418805 ↗ |
| Known as | Ibuprofen extrudate | “Drug: Ibuprofen extrudate” NCT02183012 ↗ |
| Known as | Ibuprofen Kabi | “Group A will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Ibuprofen B.Braun/Ibuprofen Kabi...” NCT07024199 ↗ |
| Known as | Ibuprofen lysinate | “Drug: Ibuprofen lysinate” NCT02183012 ↗ |
| Known as | ibuprofen sodium | “subjects were randomized 2:2:1 to receive a single oral dose of ibuprofen sodium tablets (Advil® Film Coated; 2 × 256 mg [equivalent to 400 mg standard ibuprofen]), standard...” PMID 26819724 ↗ Apr 20151“Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo.” PMID 25526232 ↗ Dec 2014 |
| Known as | Ibuprofen Syrup | “COTA arm (Ibuprofen Syrup and EMLA Cream)” NCT04337814 ↗ |
| Known as | ibuprofen tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04328805 ↗ |
| Known as | Ibuprofen-Najo | “When one or two dominant follicles (18 mm in diameter) observed, the final stage of oocyte maturation will be induced with triptorelin 100 μg (Decapeptyl®; Ferring GmbH,...” NCT02732808 ↗ |
| Known as | Ibuprofen/Advil/Motrin | “Ibuprofen/Advil/Motrin” NCT02029235 ↗ |
| Known as | Ibuprofène | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04330547 ↗ |
| Known as | Ibuprophen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01666587 ↗ |
| Known as | Ibuvix | “Ibuvix® - ibuprofen” NCT04637529 ↗ |
| Known as | Intrafen | “400mg of ibuprofen(intrafen 400mg/4ml Gen ilaç sanayi, Turkey) intravenous (IV) was given 100 patients” NCT03918135 ↗ |
| Known as | Intrafen Flk | “800mg Ibuprofen (Intrafen Flk, Gen drug, Turkey) in 150 ml normal saline given as a slow intravenous infusion over 5 minutes” NCT02836509 ↗ |
| Known as | IVIb | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00867880 ↗ |
| Known as | LG-ibuprofen | “Two studies evaluated the analgesic onset, efficacy, and safety of this fast-acting acetaminophen (FA-acetaminophen) tablet relative to commercial acetaminophen caplets...” PMID 38124555 ↗ Jan 2024 |
| Known as | M01A E01 Ibuprofen | “M01A E01 Ibuprofen” NCT00699114 ↗ |
| Known as | Midol IB | “Midol IB” NCT04432597 ↗ |
| Known as | Motrin | “subjects were randomized 2:2:1 to receive a single oral dose of ibuprofen sodium tablets (Advil® Film Coated; 2 × 256 mg [equivalent to 400 mg standard ibuprofen]), standard...” PMID 26819724 ↗ Apr 201514“Study of Bleeding Tendency, Platelet Function, and Pharmacokinetics of Azidothymidine (AZT) and Motrin (Ibuprofen) in HIV-Infected Hemophiliacs” NCT00002276 ↗ “Currently, when a child has fever either ibuprofen (e.g. Motrin, Advil) or acetaminophen (e.g. Tylenol) is given.” NCT00267293 ↗ “Ibuprofen (Advil, Motrin) is a widely available, cheap, and commonly used over the counter NSAID.” NCT05512754 ↗ “Ibuprofen (also known as Advil or Motrin) is a medication that is known to reduce pain.” NCT01681667 ↗ “800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))” NCT02966288 ↗ “Motrin - also known as ibuprofen 800 mg every 6 hours; not to exceed 3200 mg/day” NCT06113211 ↗ “You may know ibuprofen by the name Advil or Motrin.” NCT01938040 ↗ “ibuprofen (also known as Motrin or Advil)” NCT04905563 ↗ “Ibuprofen (Motrin®, Pfizer S.A. de C.V.)” NCT05428306 ↗ “Tylenol/Motrin” NCT03528343 ↗ |
| Known as | Motrin IB | “reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)” NCT05729555 ↗1“Motrin IB Ibuprofen Tablets 200 mg” NCT03418805 ↗ |
| Known as | Motrin IB Ibuprofen Tablets 200 mg | “Motrin® IB Ibuprofen Tablets 200 mg” NCT03418805 ↗ |
| Known as | Motrin, Advil (Ibuprofen) | “Motrin, Advil (Ibuprofen)” NCT02153177 ↗ |
| Known as | Neoprofen | “Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen)” NCT05340582 ↗ |
| Known as | NeoProfen (R) | “ibuprofen l-lysine iv solution (NeoProfen (R) )” NCT00440804 ↗ |
| Known as | nonsteroidal anti-inflammatory drug (NSAID) | “nonsteroidal anti-inflammatory drug (NSAID)” NCT01377441 ↗ |
| Known as | Nurfen | “Those randomized to Group A (active) received the NSAID in the study, which was oral commercially-available Nurfen® syrup containing the NSAID ibuprofen.” NCT04476069 ↗ |
| Known as | Nurofen | “Ibuprofen (Nurofen\*) is known as an effective medication to reduce fever in infectious illnesses and is even considered as superior to paracetamol.” NCT00954200 ↗4“Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours” NCT06212830 ↗ “RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.” NCT03180879 ↗ “400 mg ibuprofen(Nurofen)” NCT03225352 ↗ |
| Known as | Nurofen dla dzieci Forte pomarańczowy | “the reference medication (Ibuprofen 4% oral suspension marketed under the trade name Nurofen dla dzieci Forte pomarańczowy 40 mg/mL, oral suspension)” NCT07036861 ↗ |
| Known as | Nurofen Immedia | “Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules” NCT03184766 ↗1“Ibuprofen (Nurofen Immedia®)” NCT01879371 ↗ |
| Known as | Peinlos | “Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.” NCT06604598 ↗ |
| Known as | S (+) - Ibuprofen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04772781 ↗ |
| Known as | Spalt forte | “oral fasted administration of Spalt forte 400 mg Weichkapseln (Pfizer Consumer Healthcare GmbH, Germany), containing 400 mg ibuprofen” NCT03018015 ↗ |
| Known as | SST-0225 | “SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.” NCT02339129 ↗ |
| Known as | standard ibuprofen | “subjects were randomized 2:2:1 to receive a single oral dose of ibuprofen sodium tablets (Advil® Film Coated; 2 × 256 mg [equivalent to 400 mg standard ibuprofen]), standard...” PMID 26819724 ↗ Apr 2015 |
| Known as | VALE-ibuprofen | “OBJECTIVE: Investigate the safety and efficacy of a novel transdermal ibuprofen formulation (VALE®-ibuprofen) containing 10% ibuprofen, compared to a placebo in a randomized,...” PMID 24284856 ↗ Nov 2013 |
| Action | Inhibit | “We tested the hypotheses that a reduction in prostaglandin synthesis by ibuprofen treatment during fasting decreased renal water and sodium excretion.” PMID 21029429 ↗ Oct 2010 |
| Modality | Small molecule | “The NSAID ibuprofen has antiinflammatory and analgesic properties” PMID 19843482 ↗ Sep 2009 |
| Route | Intravenous | “ibuprofen given intravenously every six hours” NCT00000574 ↗ |
| Target | PPARG | “Furthermore, we performed a pilot randomised controlled trial to determine the effect of the PPARG Pro(12)Ala polymorphism and the PPARγ stimulator Ibuprofen on sex-hormone...” PMID 27102200 ↗ Apr 2016 |